US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VanEck Uranium+Nuclear Energy ETF

84.88

+0.40000.47%

Post-market: 88.003.12+3.68%19:43 EDT

Volume:155.86K

Turnover:13.28M

Market Cap:1.10B

PE:- -

High:86.78

Open:86.78

Low:84.57

Close:84.48

Loading ...

Overview Company News Filings

Concept

AI Power Stocks-0.30%

Capital Flow

Inflow:

Outflow:

News

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Press Release: Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NLR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NLR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NLR\",,,,,undefined,":{"symbol":"NLR","market":"US","secType":"STK","nameCN":"VanEck Uranium+Nuclear Energy ETF","latestPrice":84.88,"timestamp":1747080000000,"preClose":84.48,"halted":0,"volume":155856,"hourTrading":{"tag":"盘后","latestPrice":88,"preClose":84.88,"latestTime":"19:43 EDT","volume":1052,"amount":91806.185,"timestamp":1747093421687},"delay":0,"floatShares":12916632,"shares":12916632,"eps":0,"marketStatus":"Closed","change":0.4,"latestTime":"05-12 16:00:00 EDT","open":86.78,"high":86.78,"low":84.5677,"amount":13281571.40064,"amplitude":0.026187,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747123200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":84.48,"sharesOutstanding":12691632,"nav":84.40385,"aum":1071222550.94,"bidAskSpread":0.003957,"preHourTrading":{"tag":"盘前","latestPrice":86.93,"preClose":84.48,"latestTime":"09:29 EDT","volume":277,"amount":23967.42777,"timestamp":1747056577607},"postHourTrading":{"tag":"盘后","latestPrice":88,"preClose":84.88,"latestTime":"19:43 EDT","volume":1052,"amount":91806.185,"timestamp":1747093421687},"volumeRatio":1.246423,"impliedVol":0.3122,"impliedVolPercentile":0.8},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NLR\",,,,,undefined,":{"symbol":"NLR","floatShares":12916632,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.246423,"shares":12916632,"dividePrice":0.6142,"high":86.78,"amplitude":0.026187,"preClose":84.48,"low":84.5677,"week52Low":64.26,"pbRate":"--","week52High":97.89,"institutionHeld":0,"latestPrice":84.88,"eps":0,"divideRate":0.007236,"volume":155856,"delay":0,"ttmEps":0,"open":86.78,"prevYearClose":81.34,"prevWeekClose":84.48,"prevMonthClose":78.94,"prevQuarterClose":73.27,"fiveDayClose":80.89,"twentyDayClose":73.85,"sixtyDayClose":91.71},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NLR\",params:#limit:6,delay:false,,,undefined,":[{"market":"US","name":"AI Power Stocks","bkCode":"BK4606","id":"package_us_concept_aidlg","changeRate":-0.003014}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NLR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531303571","title":"BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified","url":"https://stock-news.laohu8.com/highlight/detail?id=2531303571","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531303571?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:30","pubTimestamp":1746012600,"startTime":"0","endTime":"0","summary":"Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study. Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits. Positive delayed-type hypersensitivity   and a favorable Neutrophil-to-Lymphocyte Ratio   linked to longer progression-free survival  in Phase 3 patients. Presence of Circulating Tumor Cells  after patients’ initial Phase 3 treatment supports role as negative prognostic marker . Bria-IMT Phase 3 regimen was well-tolerated with a preferred tolerability profile. “Using biomarkers as powerful instruments to predict patient responsiveness to the Bria-IMT treatment would allow physicians and oncologists to identify potential responders sooner, providing better clinical outcomes and ultimately extending patients’ lives,” stated Carmen Calfa, MD, Clinical Research Lead for the breast site disease group at the University of Miami Miller School of Medicin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-reports-breaker-phase-3-113000083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PFS","BK4129","BK4139","BK4097","BK4211","BK4195","NLR","CAML","TPC","BCTX","OS","DTH","BK4606","BCTXZ","BCTXW"],"gpt_icon":0},{"id":"2522222180","title":"Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2522222180","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522222180?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:00","pubTimestamp":1742904000,"startTime":"0","endTime":"0","summary":"NEW YORK, March  25, 2025  (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, annou","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/25/3048658/0/en/Indaptus-Therapeutics-Chief-Medical-Officer-Roger-Waltzman-M-D-M-B-A-to-Moderate-Panel-at-CMO360-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","NLR","BK4606","SMMF","BK4211","BK4139"],"gpt_icon":0},{"id":"2520678244","title":"Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2520678244","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520678244?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:00","pubTimestamp":1742299200,"startTime":"0","endTime":"0","summary":"New trial arm to evaluate safety, dosing and preliminary anti-tumor activity in advanced solid tumors. NEW YORK, March 18, 2025  -- Indaptus Therapeutics, Inc. , a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that it has advanced toa new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.Jeffrey Meckler, CEO of Indaptus, commented, “This marks a pivotal step forward for Indaptus and our Decoy platform. Preclinical research has consistently shown that Decoy20 works synergistically with a checkpoint inhibitor, and we now have the opportunity to test that in patients for the first time. While this initial phase will focus on safety and tolerability, we are laying the groundwork for what could be a game-changin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/indaptus-therapeutics-initiates-phase-1-120000013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PD","BK4606","LU1169590202.USD","BK4023","LENZ","NLR","LU1169589451.USD","INDP","BK4139"],"gpt_icon":1},{"id":"2519386248","title":"Press Release: Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519386248","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519386248?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:30","pubTimestamp":1741865400,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update. -- Company Achieves Key Clinical Milestone with more than 20 Patients. Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20. -- Pharmacodynamic immune activation biomarker and pharmacokinetics profiles. in initial data sets appear to meet or exceed initial expectations. -- Early signs of potential benefit emerge with some patients demonstrating. Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, \"We continue to make significant progress in our Phase 1 trial of Decoy20, and enrolling more than 20 patients in the weekly dosing cohort marks an important milestone. We are particularly encouraged by the emerging clinical data, with some patients in this cohort demonstrating stable disease - an early sign that Decoy20's immune-modulating approach may be having a meaningful impact. With a favorable safety profile observed so far, we are focused on efficiently a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4080","BK4139","INDP","SITC","BK4231","BK4606","NLR"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NLR\",params:#limit:5,,,undefined,":[{"date":"2024-12-23","symbol":"NLR","amount":0.6142,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"核能指数ETF-Market Vectors","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"NLR","amount":3.258,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"核能指数ETF-Market Vectors","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"NLR","amount":1.1093,"defaultRemindTime":1671460200000,"name":"核能指数ETF-Market Vectors","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"NLR","amount":1.091,"defaultRemindTime":1640010600000,"name":"核能指数ETF-Market Vectors","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000},{"market":"US","date":"2020-12-21","symbol":"NLR","amount":1.0964,"name":"核能指数ETF-Market Vectors","recordDate":"2020-12-28","payableDate":"2020-12-22","currency":"USD","type":"dividend","dateTimestamp":1608526800000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NLR\",market:\"US\",,,undefined,":[{"executeDate":"2015-12-21","recordDate":"2015-12-23","paymentDate":"2015-12-28","value":1.486,"currency":"USD"},{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":1.719,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":1.936,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":1.072,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":1.0964,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NLR\",market:\"US\",delay:false,,,undefined,":{}}}